Scripps Research Secures $4 Million Grant for Groundbreaking Study

Scripps Research has been awarded a significant grant of $4 million from the California Institute for Regenerative Medicine (CIRM). This funding will support research into haploinsufficiency, a genetic condition where only one copy of a crucial gene functions, leading to various neurodevelopmental disorders. These disorders can include severe, treatment-resistant epilepsy, which affects countless individuals and families.

Exploring Neurodevelopmental Disorders

Leading the project is Giordano Lippi, a neuroscientist at Scripps Research. Collaborating with him are two co-investigators from UC San Diego: molecular biologist Gene Yeo and pediatric neurologist Dr. Olivia Kim Mcmanus. Together, they will utilize pluripotent stem cells to develop cortical organoids, which are lab-created structures that can replicate the function of brain cell networks. This innovative approach will enable a detailed investigation into how genetic abnormalities influence neuronal activity.

The research aims to create conditions that mimic the brain’s environment, thereby facilitating insights into possible treatments for haploinsufficiency. This condition typically results in the underproduction of essential proteins due to the inactivity of one gene copy. “We are developing a technology that can effectively ‘turn the volume back up’ on genes in which one copy has been silenced,” Lippi stated. He emphasized that restoring protein levels may lead to new therapeutic avenues for complex neurodevelopmental disorders.

Funding for Stem Cell Research

CIRM was established in 2004 following the passage of Proposition 71, which allowed for research using human embryonic stem cells in response to a federal ban. The institute sold $3 billion in bonds, directing these funds to researchers across California who are focused on utilizing stem cells to investigate and treat various diseases. In 2020, voters approved an additional $5.5 billion in funding through Proposition 14, further bolstering the institute’s efforts.

According to CIRM, the funding it has distributed has directly supported 116 clinical trials and has established a network of nine “alpha clinics,” including UC San Diego. These clinics have conducted over 250 additional stem cell trials, making significant contributions to the field of regenerative medicine.

The collaboration between Scripps Research and UC San Diego is poised to advance understanding of haploinsufficiency and its effects on neurodevelopment. The research not only holds promise for scientific discovery but also for the potential to improve the lives of patients affected by debilitating neurodevelopmental conditions.